Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 16, 2026
TickeronGET DAILY SIGNALS
CGEM vs. ORMP: Cullinan Therapeutics' Clinical Focus Compared to Oramed's Diversified Holdings

CGEM vs. ORMP: Cullinan Therapeutics' Clinical Focus Compared to Oramed's Diversified Holdings

Key Takeaways

  • CGEM is a clinical-stage biopharmaceutical company advancing oncology and immunology "T cell engager" candidates, while ORMP has pivoted into a diversified operating and strategic-investment company following the transfer of its oral drug-delivery platform.
  • CGEM carries a broadly positive analyst posture and a near-term catalyst calendar, whereas ORMP's value is increasingly tied to its investment portfolio and balance sheet rather than a single drug pipeline.
  • Relative performance and momentum favor CGEM, whose risk is concentrated in clinical and regulatory outcomes; ORMP offers a more diversified, lower-velocity profile with a notable dividend yield.
  • Tickeron AI Verdict: CGEM — based on trend consistency, catalyst density, and market positioning, the AI currently leans toward Cullinan Therapeutics.
  • Explore CGEM Major News and CGEM Today's Price Move, as well as ORMP Major News and ORMP Today's Price Move, for deeper, ticker-specific coverage.
  • For a broader view of data-driven trading strategies, explore the curated Trending AI Robots section.

Introduction

Investors weighing two very different healthcare-related names may find this stock comparison instructive. CGEM, Cullinan Therapeutics, is a clinical-stage biotechnology company built around T cell engagers for cancer and autoimmune disease. ORMP, Oramed Pharmaceuticals, has transformed from an oral drug-delivery developer into a diversified operating and investment company. Although both trade on Nasdaq and share a healthcare lineage, their business models, risk profiles, and growth drivers diverge sharply. This comparison is most relevant for traders and investors assessing relative performance, catalyst-driven momentum, and market positioning between a concentrated clinical pipeline and a balance-sheet-oriented holding structure.

CGEM Overview and Recent Performance

Cullinan Therapeutics is a clinical-stage biopharmaceutical company advancing a portfolio of bispecific T cell engagers — engineered antibodies designed to redirect immune cells against disease targets — across oncology and immunology. Recent market activity has been driven by a dense stream of pipeline milestones. The company reported interim Phase 1b/2a data for velinotamig, a BCMA-directed T cell engager, in systemic lupus erythematosus (SLE), showing complete renal responses in several patients. It has also advanced zipalertinib, an EGFR inhibitor developed with partner Taiho, toward regulatory review for non-small cell lung cancer (NSCLC), and initiated a registrational Phase 2 study of CLN-049 in acute myeloid leukemia (AML). These catalysts, combined with a cash runway management has guided into 2029 and a predominantly "Buy" analyst consensus, have supported constructive sentiment, though shares remain volatile around clinical readouts and broader biotech risk appetite. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

ORMP Overview and Recent Performance

Oramed Pharmaceuticals has undergone a strategic repositioning. The company transferred its Protein Oral Delivery (POD) platform to Lifeward in exchange for a significant equity stake, shifting its identity toward a diversified operating company that deploys capital across biomedical and broader investments. Its balance sheet has strengthened, with total cash and assets reported near $270 million earlier in 2026, and its stake in Alpha Tau Medical has appreciated substantially. Oramed has also received meaningful repayments on its Scilex loan, and it was added to the Russell 2000 and Russell 3000 indexes. In recent weeks, ORMP has traded with relatively lower volatility than CGEM and carries an unusually high dividend yield for the sector. However, its growth narrative now depends more on portfolio appreciation and deal execution than on clinical data, which reduces catalyst-driven price swings relative to a pure biotech.

Head-to-Head Comparison

The core contrast between these two names is concentration versus diversification. CGEM is a pure-play biotech whose valuation hinges on clinical and regulatory outcomes, giving it higher beta-like sensitivity to individual data readouts. ORMP is effectively a holding company whose value derives from a portfolio of equity stakes, loans, and royalties, producing a steadier but less explosive return profile. On growth drivers, CGEM offers near-term catalysts in oncology and immunology, while ORMP relies on the appreciation and monetization of its investments, such as Alpha Tau and Scilex. Risk factors differ accordingly: CGEM faces binary clinical-trial risk and dilution potential, whereas ORMP faces concentration risk in a handful of portfolio positions and thinner analyst coverage. Market sentiment currently appears more constructive toward CGEM, reflected in a stronger consensus rating and price-target upside, while ORMP's appeal centers on its balance sheet, dividends, and discounted valuation. From what I see, this divergence shows up clearly when comparing momentum signals across the two.

Tickeron AI Verdict

Weighing trend consistency, catalyst density, and relative positioning, Tickeron's AI would currently lean toward CGEM. Cullinan Therapeutics combines a data-rich near-term pipeline calendar with a predominantly positive analyst stance and a clearly defined clinical roadmap, factors that tend to register as more consistent momentum signals in an automated framework. ORMP's diversified structure and yield offer stability but fewer discrete catalysts for directional price movement. This assessment is probabilistic rather than definitive: it reflects observable market positioning at this time and could shift as clinical results, regulatory decisions, and portfolio developments unfold.

Exploring Data-Driven Trading Approaches

I frequently review Tickeron’s Trending AI Robots when evaluating names like these. The section highlights automated strategies that have performed well in current conditions, covering a range of styles, timeframes, and ticker sets. It provides a practical way to identify systematic approaches that align with specific objectives without extensive manual work, and the curation updates to match evolving market environments.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ORMP, CGEM

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


ORMP's Indicator enters downward trend

The Aroon Indicator for ORMP entered a downward trend on November 16, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 184 similar instances where the Aroon Indicator formed such a pattern. In 151 of the 184 cases the stock moved lower. This puts the odds of a downward move at 82%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ORMP as a result. In 72 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.

The Moving Average Convergence Divergence Histogram (MACD) for ORMP turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 42 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ORMP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ORMP's RSI Indicator exited the oversold zone, 25 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 48 of 62 cases where ORMP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.

ORMP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. ORMP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.506) is normal, around the industry mean (3.586). P/E Ratio (0.910) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.259) settles around the average of (130.981) among similar stocks. P/S Ratio (90.909) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ORMP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -10%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was -22%. PEPG experienced the highest price growth at 75%, while ALGS experienced the biggest fall at -58%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -24%. For the same stocks of the Industry, the average monthly volume growth was 6% and the average quarterly volume growth was -35%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 43
Price Growth Rating: 65
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company which engages in pharmaceutical preparations

Industry Biotechnology

Industry
Pharmaceuticals Other
Address
1185 Avenue of the Americas
Phone
+1 844 967-2633
Employees
13
Web
https://www.oramed.com
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.
SKHY fell -6.87% to $122.74 by 10:04 a.m. ET, down $9.05 from Friday's close of $131.79, extending a premarket decline into the regular session. The drop was driven by a sector-wide AI chip selloff ahead of Nvidia's quarterly results on Tuesday, where CEO Jensen Huang's resignation has raised doubts about the durability of data-center spending that underpins high-bandwidth memory demand.
Dell Technologies (DELL) fell roughly 23.7% over the last 30 days, sliding from a closing price of $451.71 on October 16, 2026, to $344.53 on November 13, 2026. The decline accelerated after the U.S. midterm elections, when investor concerns about potential AI and data-center regulation triggered a sharp sell-off across AI hardware names.